telmisartan has been researched along with Parkinsonian Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhat, A; Chidambaram, SB; Essa, MM; Guillemin, GJ; Mani, S; Manivasagam, T; Rajamani, B; Ray, B; Sekar, S; Thenmozhi, AJ | 1 |
| Babu, CS; Kalaivani, P; Priya, RJ; Ranju, V; Sathiya, S; Sumathy, H; Sunil, AG | 1 |
2 other study(ies) available for telmisartan and Parkinsonian Disorders
| Article | Year |
|---|---|
Telmisartan Ameliorates Astroglial and Dopaminergic Functions in a Mouse Model of Chronic Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Angiotensin II Type 1 Receptor Blockers; Animals; Astrocytes; Chronic Disease; Corpus Striatum; Disease Models, Animal; Dopamine; Gene Expression Regulation; Glutathione; Male; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Nitric Oxide; Parkinsonian Disorders; Psychomotor Disorders; Substantia Nigra; Telmisartan; Walking | 2018 |
Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
Topics: alpha-Synuclein; Angiotensin II Type 1 Receptor Blockers; Animals; Behavior, Animal; Benzimidazoles; Benzoates; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Gait; Gene Expression; Glial Cell Line-Derived Neurotrophic Factor; Glial Fibrillary Acidic Protein; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neuroprotective Agents; Parkinsonian Disorders; Substantia Nigra; Telmisartan; Tyrosine 3-Monooxygenase; Vesicular Monoamine Transport Proteins | 2013 |